SCHEDULE 13D: Ligand Pharmaceuticals Secures Major Stake in Pelthos Therapeutics Following Strategic Merger and $18M PIPE Financing

Ligand Pharmaceuticals Incorporated has become a significant beneficial owner of Pelthos Therapeutics Inc., holding 49.9% of its common stock, following the completion of a merger and a private investment in public equity (PIPE) financing.

Summary

• Ligand Pharmaceuticals Incorporated acquired 49.9% beneficial ownership of Pelthos Therapeutics Inc. (formerly Channel Therapeutics Corporation), effective July 1, 2025.
• This ownership includes 1,500,000 shares of Common Stock and 34,278.681 shares of Series A Convertible Preferred Stock.
• The acquisition resulted from a merger where Pelthos acquired LNHC, Inc., a wholly-owned subsidiary of Ligand, which held assets of Novan, Inc. previously acquired by Ligand in September 2023.
• Ligand also participated in a PIPE financing, purchasing 18,000 shares of Series A Preferred Stock for $18.0 million, with the cash purchase price reduced by the cancellation of approximately $12.7 million in bridge notes Ligand had advanced to LNHC.
• The combined company began operating as Pelthos Therapeutics Inc. on July 1, 2025, following a one-for-ten reverse stock split.
• Ligand immediately converted 15,000 shares of Series A Preferred Stock into 1,500,000 shares of Common Stock upon closing.
• Ligand's beneficial ownership and aggregate voting rights are capped at 49.9% of the Common Stock outstanding, based on 3,029,501 shares of Common Stock and 57,568.68 shares of Series A Preferred Stock outstanding.

Sentiment

Score: 7

Explanation: The document describes the successful completion of a strategic merger and significant investment by Ligand Pharmaceuticals into Pelthos Therapeutics. This indicates a positive step for Pelthos, securing funding and strategic partnership. The clear outline of ownership, governance, and future intentions suggests a well-structured transaction. The 49.9% cap on ownership and voting, while a limitation, is a common and expected structure in such strategic investments. The lock-up agreement is standard for such transactions.

Positives

• Ligand Pharmaceuticals has secured a significant strategic stake (49.9%) in Pelthos Therapeutics, indicating a strong commitment and potential for influence.
• The transaction consolidates assets from Novan, Inc. (via LNHC) under Pelthos, potentially streamlining operations and leveraging synergies.
• The PIPE financing provided $18.0 million in capital to Pelthos, with a significant portion ($12.7 million) offsetting bridge notes, strengthening the company's financial position for commercial launch activities like ZELSUVMI.
• Ligand's CEO and SVP joining Pelthos' board provides direct oversight and strategic guidance from a major investor.

Negatives

• Ligand's beneficial ownership and voting rights are capped at 49.9%, limiting full control despite a substantial investment.
• The lock-up agreement restricts Ligand's ability to sell or transfer shares until December 31, 2025, limiting liquidity for a period.

Risks

• Ligand's ability to convert Series A Preferred Stock is limited to prevent exceeding 49.9% beneficial ownership of Common Stock, which could restrict future flexibility.
• The lock-up agreement prevents Ligand from disposing of shares until December 31, 2025, which could pose a liquidity risk if market conditions change unfavorably.
• Future actions by Ligand, such as acquiring more securities, selling holdings, or proposing extraordinary corporate transactions (merger, take-private, asset sales, changes to capitalization/dividend policy, management/board changes), could introduce uncertainty or significant shifts for the Issuer.

Future Outlook

Ligand Pharmaceuticals intends to continuously review its investment in Pelthos Therapeutics. Future actions may include acquiring additional securities, selling existing holdings, or engaging in discussions regarding extraordinary corporate transactions such as mergers, reorganizations, take-private transactions, asset sales, changes to capitalization or dividend policy, or alterations to management or board composition.

Management Comments

• Todd C. Davis, who serves as the Chief Executive Officer and as a director of Ligand, and Richard Baxter, who serves as Senior Vice President, Investment Operations, of Ligand, were elected to the Board of Directors of the Issuer.
• As directors of the Issuer, Messrs. Davis and Baxter may have the ability to affect and influence control of the Issuer until such time of their resignation.

Industry Context

This transaction represents a strategic move by Ligand Pharmaceuticals, a company focused on acquiring royalty-generating assets in the pharmaceutical industry, to integrate a new therapeutic entity (Pelthos, with assets from Novan, including ZELSUVMI) into its portfolio. This aligns with a broader industry trend of larger pharmaceutical or biotech companies acquiring smaller, specialized firms or their assets to expand pipelines and market reach, particularly in areas with commercial launch potential. The focus on ZELSUVMI suggests an interest in dermatology or related therapeutic areas.

Comparison to Industry Standards

• The acquisition of assets from a company in bankruptcy (Novan, Inc.) is a common strategy in the pharmaceutical industry for acquiring valuable intellectual property or commercial-stage assets at a potentially lower cost.
• The use of a PIPE financing alongside a merger is a standard mechanism for private capital infusion into a public company, especially when a strategic investor is involved, providing immediate funding for operations or commercialization efforts.
• The 49.9% beneficial ownership and voting cap is a common structure in strategic investments to avoid triggering certain regulatory thresholds or to maintain a degree of independence for the acquired entity while still providing significant influence.
• The inclusion of key executives from the acquiring company (Ligand) on the target company's (Pelthos) board is a typical corporate governance practice to ensure alignment of interests and strategic oversight post-acquisition.
• The one-for-ten reverse stock split is a common action for companies post-merger or restructuring to increase share price and meet listing requirements, often seen in smaller biotech or pharma companies.

Management Changes

Corporate Governance

Related Party Transactions

• Ligand Pharmaceuticals, as a significant investor and now with board representation, engaged in a PIPE financing with Pelthos Therapeutics Inc.
• The PIPE financing involved Ligand purchasing 18,000 shares of Series A Preferred Stock for $18.0 million, with approximately $12.7 million of this offset by the cancellation of bridge notes Ligand had previously advanced to LNHC (a wholly-owned subsidiary of Ligand that merged into Pelthos).
• Ligand received 31,278.681 shares of Series A Preferred Stock in the Merger as consideration for its LNHC shares.
• Ligand entered into a Registration Rights Agreement and a Lock-Up Agreement with the Issuer.

Stakeholder Impact

• Shareholders: Existing shareholders of Pelthos Therapeutics will see significant dilution from the issuance of new shares in the PIPE financing and merger, but also benefit from the capital infusion and strategic partnership with Ligand. The reverse stock split impacts the number of shares held but not the total value. The lock-up agreement provides stability by preventing immediate large-scale selling by key parties.
• Employees: The merger and integration of LNHC assets into Pelthos could lead to organizational restructuring, potentially impacting employees of both entities. The focus on commercial launch of ZELSUVMI suggests continued operational activity.
• Customers: The commercial launch of ZELSUVMI, supported by the new capital, could lead to increased product availability and marketing efforts, benefiting potential customers.
• Creditors: The cancellation of bridge notes owed to Ligand as part of the PIPE financing strengthens Pelthos' balance sheet by reducing debt.

Next Steps

• Ligand Pharmaceuticals will continuously review its investment in Pelthos Therapeutics.
• Ligand may acquire additional securities of Pelthos or sell existing holdings.
• Ligand may engage in discussions with Pelthos management, board, and other securityholders regarding potential extraordinary corporate transactions (e.g., merger, reorganization, take-private, asset sales, changes to capitalization/dividend policy, management/board changes).
• Pelthos Therapeutics will prepare and file a resale registration statement with the SEC on or prior to the later of 30 days following the PIPE closing or 15 calendar days after the due date of the next periodic report.
• Pelthos will use reasonable best efforts to cause the registration statement to be declared effective by the SEC within 120 calendar days of the PIPE closing (or 150 calendar days if SEC reviews).

Key Dates

Recommendation

Keywords

Pelthos Therapeutics, Ligand Pharmaceuticals, SEC Schedule 13D, Merger, PIPE Financing, Common Stock, Series A Preferred Stock, Beneficial Ownership, Corporate Governance, Pharmaceutical Industry, Novan Inc., ZELSUVMI, Reverse Stock Split, Registration Rights, Lock-Up Agreement